Time to Buy CNS Pharmaceuticals (CNSP) Stock For Its Berubicin?

Two hours ago CNS Pharmaceuticals (CNSP) stock started surging and right now it is soaring 17% on six million volume. This sudden jump is surely backed by positive news that just came out in a form of a press release.

CNSP stock may keep jumping this year

Today Swissmedic, the Swiss Agency for Therapeutic Products approves CNS to treat recurrent glioblastoma multiforme (GBM) as the company has a potentially pivotal study of Berubicin, an innovative first in its class anthracycline to appear to cross over the blood-brain barrier and kill tumor cells as a potential treatment option for glioblastoma. Having the potential candidate gives CNS a strong competitive advantage in the long run. If the treatment ends positively CNSP shares will blow up the market.

cnsp stock